Cover Image
市場調查報告書

全球HIV感染疾病藥市場·開發平台分析

Global HIV Infection Drug Market & Pipeline Insight

出版商 KuicK Research 商品編碼 310627
出版日期 內容資訊 英文 1350 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球HIV感染疾病藥市場·開發平台分析 Global HIV Infection Drug Market & Pipeline Insight
出版日期: 2014年08月18日 內容資訊: 英文 1350 Pages
簡介

本報告提供全球HIV感染疾病藥市場相關調查,彙整市場概要與發病率狀況,FDA和EMA的HIV治療藥開發法規,全球HIV感染疾病治療藥開發平台,HIV臨床實驗平台及專利分析等,為您概述為以下內容。

第1章 全球HIV感染疾病藥市場概要

  • 全球HIV發病率情形
  • 市場概要:全球·地區
  • 臨床實驗平台概要

第2章 全球HIV感染疾病藥市場上動態

  • 可望的推動市場要素
  • 應該解決的市場課題
  • 未來的機會展望

第3章 HIV疫苗開發的FDA法律規範

  • 兒童族群用預防性HIV疫苗的開發
  • 抗HIV資料提出指南
  • 開發抗逆轉錄病毒上的HIV阻力檢驗
  • HIV-1幹線:治療用抗逆轉錄病毒藥的開發

第4章 治療HIV感染用的醫藥品開發之EMA法律規範

第5章 全球HIV感染藥的臨床實驗平台:階段·企業·各國

  • 階段不明
  • 研究
  • 前臨床
  • 臨床
  • 階段0
  • 階段I
  • 階段I/II
  • 階段II
  • 階段III
  • 階段
  • 登記前
  • 登記完畢

第6章 已上市HIV治療藥臨床簡介:企業·各國

第7章 臨床實驗平台上的停止·中止HIV治療藥:階段·企業·各國

  • 沒有開發報告
  • 中止
  • 停止

第8章 競爭情形

  • Antigen Express
  • Bionor Pharma
  • FIT Biotech
  • Gilead Sciences
  • GeoVax
  • GenVec
  • Glaxo Smithkline
  • Immune Response BioPharma
  • Inovio Pharmaceuticals
  • Novartis
  • Sanofi Pasteur
目錄

The rate of HIV infection and the number of deaths due to AIDS has been on a declining note at a positive rate across the globe. It has been estimated that the death rate reduced from 2.3 million in 2005 to 1.5 in 2013, with the rates for children being even much lower. A major cause for such drastic changes in the infection rates has been the improved access to antiretroviral drugs and therapy in recent years. The access to these drugs and therapy has improved significantly, particularly in many developing countries where these drugs and treatments were previously not available at all. At present these solutions have been made accessible and affordable also.

However, a major trend observed in this market has been that although the HIV infection rates are falling, the number of new patients being affected by the virus is increasing. With all the conscious efforts undertaken by all the related organizations and stakeholders, it is expected that by 2015, significant investments would be recorded in this field with the WHO setting an aim to treat close to 15 million HIV patients.

In terms of the market, with the rising popularity of this disease and the growing efforts to combat its spread, it is most likely that an increasing number of companies would enter this market, which would, in the long run, reduce the overall cost of drugs owing to increased competition among the players. Additionally, economies of scale would also be a major factor driving down the cost of drugs targeted for the HIV virus infected people. This in turn would make the drugs and treatment options more affordable.

It is expected that in the next 5-8 years, the pharmaceutical companies would focus more on the development of a successful efficient vaccine to control the spread of this disease. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. There needs to be complete scrutiny of every single technological area of HIV prevention R&D so as to reflect the best methods of channelizing the funds which are limited in nature. The funds need to be specifically directed towards only those products and approaches which have a high probability of succeeding, instead of those which are less promising.

"Global HIV Infection Drug Market & Pipeline Insight" Report Highlight:

  • Global HIV Infection Drug Market Overview & Incidence Scenario
  • FDA & EMA Regulation for Development of HIV Drug
  • Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country
  • Global HIV Clinical Pipeline: 315 Drugs in Development Phases
  • Majority HIV Drug in Preclinical Phase: 144 Drugs
  • Marketed HIV Drugs: 37
  • Suspended & Discounted HIV Drug in Clinical Pipeline: 539 Drugs
  • Patent Analysis: Patent Number & Technology

Table of Contents

1. Global HIV Infection Drug Market Overview

  • 1.1 Global HIV Incidence Scenario
  • 1.2 Market Overview: Global & Regional
  • 1.3 Clinical Pipeline Overview

2. Global HIV Infection Drug Market Dynamics

  • 2.1 Favorable Market Drivers
  • 2.2 Market Challenges to be Resolved
  • 2.3 Future Opportunity Outlook

3. FDA Regulatory Framework for Development of HIV Vaccine

  • 3.1 Development of Preventive HIV Vaccines for Use in Paediatric Populations
  • 3.2 Guidance for Submitting HIV Resistance Data
  • 3.3 HIV Resistance Testing in Antiretroviral Drug Development
  • 3.4 HIV-1 Infection: Developing Antiretroviral Drugs for Treatment

4. EMA Regulatory Framework for Development of Medicinal Products For Treatment Of HIV Infection

5. Global HIV Infection Drug Clinical Pipeline by Phase, Company & Country

  • 5.1 Phase Unknown
  • 5.2 Research
  • 5.3 Preclinical
  • 5.4 Clinical
  • 5.5 Phase-0
  • 5.6 Phase-I
  • 5.7 Phase-I/II
  • 5.8 Phase-II
  • 5.9 Phase-III
  • 5.10 Preregistration
  • 5.11 Registered

6. Marketed HIV Drug Clinical Profile by Company & Country

7. Suspended & Discontinued HIV Drugs in Clinical Pipeline by Phase, Company & Country

  • 7.1 No Development Reported
  • 7.2 Discontinued
  • 7.3 Suspended

8. Competitive Landscape

  • 8.1 Antigen Express
  • 8.2 Bionor Pharma
  • 8.3 FIT Biotech
  • 8.4 Gilead Sciences
  • 8.5 GeoVax
  • 8.6 GenVec
  • 8.7 Glaxo Smithkline
  • 8.8 Immune Response BioPharma
  • 8.9 Inovio Pharmaceuticals
  • 8.10 Novartis
  • 8.11 Sanofi Pasteur
  • Figure 1-1: People Living With HIV Infection (Million), 2009-2014
  • Figure 1-2: New Incidence of HIV Infection (Million), 2009-2012
  • Figure 1-3: People Living With HIV Infection by Region (%), 2012
  • Figure 1-4: People Accessing Treatment for HIV Infection (Million), 2009-2012
  • Figure 1-5: Global - HIV/AIDS Therapeutics Market (US$ Billion), 2013-2018
  • Figure 1-6: Global - HIV Infection Drug Pipeline by Phase (%), 2014
  • Figure 1-7: Global - HIV Infection Drug Pipeline by Phase (Number), 2014
  • Figure 1-8: Global - No Development Reported in HIV Infection Drug in Pipeline by Phase (%), 2014
  • Figure 1-9: Global - No Development Reported in HIV Infection Drug in Pipeline by Phase (Number), 2014
  • Figure 1-10: Global - Discontinued HIV Infection Drug in Pipeline by Phase (%), 2014
  • Figure 1-11: Global - Discontinued HIV Infection Drug in Pipeline by Phase (%), 2014
  • Figure 1-12: Global - Suspended HIV Infection Drug in Pipeline by Phase (%), 2014
  • Figure 1-13: Global - Suspended HIV Infection Drug in Pipeline by Phase (%), 2014
Back to Top